Belzutifan’s launch time in China and explanation of patient purchasing channels

Belzutifan (Belzutifan) is a new type of oral hypoxia-inducible factor-2α (HIF-2α) Inhibitors are mainly used to treat renal cell carcinoma, kidney tumors and some other indications related to von Hippel's disease (VHL). As an emerging targeted drug in recent years, it has attracted global attention. At present, besotivan has been approved for marketing in China, providing more treatment options for relevant patients. However, since it is a new drug, the market supply is still in the stage of gradual rollout, and some areas may not yet be fully covered.

Although Bezutivan has been marketed in China, it has not yet been included in the national medical insurance directory, so patients need to pay for it in full when purchasing it domestically. Since its pricing has not yet been made public and transparent, the specific price must be determined from local hospital pharmacies or official channels. Generally, the price range is relatively high, which puts certain financial pressure on patients. If the drug can be included in medical insurance in the future, it is expected to significantly reduce patients' medication costs and improve the accessibility of treatment.

In the international market, in addition to the original version of the drug in the United States and Europe, generic drugs have been launched in some regions such as Laos. The price of the Lao version of generic drugs is about more than 5,000 yuan per bottle, which is cheaper than the domestic original drugs. Its ingredients are basically the same as the original drug, which can reduce the financial burden of patients to a certain extent. However, when choosing generic drugs, patients must pay attention to the formality of the channels and avoid purchasing drugs from unknown sources to ensure efficacy and safety.

For Chinese patients, the most formal and safe way to purchase medicines is still domestic hospital pharmacies or officially certified drug retail platforms. If you consider overseas generic drugs, you should use them through legal channels and with caution under the guidance of a doctor. Overall, the launch of besetifan has brought new treatment hope to patients, but medical insurance coverage has yet to be advanced. Prior to this, patients should comprehensively consider efficacy, safety and economic conditions, reasonably choose medication channels, and insist on standardized treatment under the guidance of professional doctors.

Reference materials:https://www.drugs.com/